Categories: CancerDiagnosticsNews

EDAP to Announce Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 30th

LYON, France, March 9, 2023 — EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2022, before the markets open on Thursday, March 30th, 2023.

An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am ET on Thursday, March 30th, 2023. Please refer to the information below for the conference call dial-in information and webcast registration.

Conference Call & Webcast
Thursday, March 30th@ 8:30am Eastern Time
Domestic:                877-451-6152
International:           201-389-0879
CallMe ™:                Link
Webcast:                 https://viavid.webcasts.com/starthere.jsp?ei=1596365&tp_key=be6fe8ba22

About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market. EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.comus.hifu-prostate.com and www.focalone.com.

Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

 

Staff

Recent Posts

Redefining the Standard of Care: Introducing the Aulisa® Monitor Camera for Advanced Patient Monitoring

PALO ALTO, Calif., Nov. 22, 2024 /PRNewswire/ -- Aulisa® Medical USA, Inc., a leader in…

4 hours ago

Defence Announces Closing of Securities for Debenture Financing

Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB:…

9 hours ago

NuGen Announces Canada-Wide Launch of InsuJet

3,250 InsuJet Starter Packs Being Delivered to Pharmacies Across CanadaToronto, Ontario--(Newsfile Corp. - November 22,…

10 hours ago

purelyIV Launches Mobile App for Seamless Wellness Management

The new app allows users to browse services, book IV therapy, manage appointments, purchase packages,…

10 hours ago

Independence Blue Cross launches Epic Payer Platform to transform care coordination and boost member health outcomes

PHILADELPHIA, Nov. 22, 2024 /PRNewswire/ -- Independence Blue Cross (IBX) is implementing the Epic Payer Platform…

10 hours ago